CV Lattes
ORCID
Abstract
Non-muscle invasive bladder cancer (NMIBC) represents approximately 70 to 80% of all bladder cancer cases. Standard treatment involves transurethral resection of the tumor followed by cycles of intravesical immunotherapy with Bacillus Calmette-Guérin (BCG). However, around 30% of patients either do not respond to treatment or experience recurrence, underscoring the urgent need for more ef…